Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026
Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026
Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026
Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026
Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026
Company Drug

ViiV Healthcare Presents Phase I Data for Ultra-Long-Acting Cabotegravir in HIV Treatment and Prevention

Fineline Cube Mar 5, 2024

GlaxoSmithKline (GSK; NYSE: GSK) unit ViiV Healthcare has presented Phase I results for an ultra-long-acting...

Company Deals

Merck Teams Up with C4 Therapeutics for Targeted Protein Degraders in Oncology

Fineline Cube Mar 5, 2024

Merck (NYSE: MRK), a Germany-headquartered science and technology company, has entered into a partnership with...

Company Digital

Innovent Biologics’ Taletrectinib Receives Second NDA Acceptance in China for ROS1 Positive NSCLC

Fineline Cube Mar 5, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that the...

Company Drug

BMS Reports Positive Long-Term Data for Zeposia in Multiple Sclerosis Trials

Fineline Cube Mar 4, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has unveiled results from several Phase III trials for...

Company Drug

BeiGene’s Brukinsa Outperforms Acalabrutinib in MAIC for Relapsed/Refractory CLL, Says BeiGene

Fineline Cube Mar 4, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the results of a matching-adjusted...

Company Drug

Merck’s Mavenclad Demonstrates Lasting Efficacy in RMS Patients, New Data Show

Fineline Cube Mar 4, 2024

Merck KGaA (ETR: MRK), a German multinational pharmaceutical, chemical, and life sciences company, has this...

Legal / IP

AlzeCure Pharma’s Alzheimer’s Drug Candidate ACD856 Receives Global Patent Awards

Fineline Cube Mar 4, 2024

AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for...

Company Deals

Sino-Biocan Secures Series B Funding to Boost Cell and Gene Therapy Production Platforms

Fineline Cube Mar 4, 2024

Sino-Biocan (Shanghai) Biotech Ltd, a provider of automated, modularized, closed cell production platforms for the...

Company Drug

AIM Vaccine Advances Pneumococcal Vaccine and Initiates Phase II Meningococcal Study

Fineline Cube Mar 4, 2024

AIM Vaccine Co., Ltd (HKG: 6660) has delivered a series of updates on the development...

Company Deals

ArkBio Partners with SDODT to Boost ADHD Treatment Marketing and Commercialization

Fineline Cube Mar 4, 2024

Shanghai Ark Biopharmaceutical Co., Ltd (ArkBio), a Chinese biopharmaceutical company, has entered into a partnership...

Company Drug

Hainan Poly Pharm Secures Tentative FDA Approval for Generic Version of UCB’s Briviact

Fineline Cube Mar 4, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Drug

BMS’s Yervoy-Opdivo Combo on Track for Breakthrough Therapy Designation in China for CRC

Fineline Cube Mar 4, 2024

The China Center for Drug Evaluation (CDE) website has indicated that the market approval filing...

Company Deals

Beijing Tinavi Medical Technologies to Form Radiotherapy Equipment JV with IM INNO and Celestial Oncology

Fineline Cube Mar 4, 2024

Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has announced its intention to establish a...

Company Drug

Pfizer’s RSV Vaccine Demonstrates Durable Efficacy with Abrysvo Phase III Results

Fineline Cube Mar 4, 2024

Pfizer Inc. (NYSE: PFE) last week reported the outcomes of a Phase III trial for...

Policy / Regulatory

Biden’s Executive Order May Restrict Data Access for China-Based Life Science Firms in the US

Fineline Cube Mar 4, 2024

US President Joe Biden last week issued an Executive Order titled “Preventing Access to Americans’...

Company Drug

Shanghai Fosun Pharma’s GCK-01 CAR-NK Cell Therapy Gets Tacit Clinical Approval from China’s CDE

Fineline Cube Mar 4, 2024

The China Center for Drug Evaluation (CDE) website has indicated that Shanghai Fosun Pharmaceutical (Group)...

Company Drug

J&J’s Rybrevant Secures Full FDA Approval for NSCLC with EGFR Exon 20 Insertions

Fineline Cube Mar 4, 2024

The US Food and Drug Administration (FDA) has granted Johnson & Johnson (J&J; NYSE: JNJ)...

Company Drug

Astellas Launches Late-Stage Trial in Japan for Nonhormonal Menopause Treatment

Fineline Cube Mar 4, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, last week initiated a late-stage...

Policy / Regulatory

Hebei Province Proposes Measures for ‘Internet+’ Medical Services and Insurance Management

Fineline Cube Mar 4, 2024

The Hebei provincial Healthcare Security Administration (HSA) bureau has released a draft set of Measures...

Company

Maruho Expands into China with New Wholly Owned Subsidiary in Beijing

Fineline Cube Mar 1, 2024

Japan-based Maruho has announced the establishment of a wholly owned subsidiary in Beijing, marking its...

Posts pagination

1 … 349 350 351 … 620

Recent updates

  • Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
  • Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
  • Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
  • GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
  • MediTrust Mabwell Insurance Ecosystem Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.